Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2011

View Archived Issues

Anchor Therapeutics presents new chemokine CXCR4 receptor agonists

Clinical investigation of NPSP-558 for hypoparathyroidism updated

Novel glucocorticoid receptor modulators may have fewer side effects than steroids

Applied Genetic Technologies receives grant for X-linked retinoschisis gene therapy

Japanese MHLW adds fenofibrate tablets to NHI price list

GetGoal-F1 results add to phase III data on lixisenatide in type 2 diabetes

Pilot trial investigates new protocol for treatment of severe pemphigus

Phase I data on Ad26.ENVA.01 in HAdV-26-seronegative and -seropositive HIV-1-uninfected adults

Randomized trial assesses estetrol in women with ER-positive early-stage breast cancer

Korean university synthesizes new PPAR-beta/delta ligands

New Mnk inhibitors patented by Boehringer Ingelheim

Spanish research teams disclose new anticancer cyclic peptides

New recombinant PEGylated FVIII molecules prepared at Novo Nordisk

Theraclone Sciences begins phase I trial of TCN-032

BMS and Ambrx establish partnership for biologics

Biofrontera submits final documents to address BF-200 ALA NDA

Zymeworks secures financing for antibody technology and pipeline programs

Acetylon Pharmaceuticals initiates phase I/IIa ACY-1215 study

ACT clear to conduct phase I/II stem cell therapy trial in U.K.

EMA committee recommends extending approval of Levemir

Shire provides update on ProAmatine in U.S.

RXi acquires worldwide license for vaccine candidate targeting gynecological cancers

EMA confirms positive benefit-to-risk balance for Multaq

ImmunoGen submits IND for anticancer candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...